Literature DB >> 11089883

Highly metastatic variant of a mouse colon carcinoma cell line, LM17 and its response to GM-CSF gene therapy.

A Ikubo1, Y Aoki, E Nagai, T Suzuki.   

Abstract

In order to establish a highly metastatic variant of a mouse colon carcinoma cell line (CT26), BALB/c mice were first subcutaneously injected with CT26 cells. Several weeks later, metastatic tumors in lungs were resected, mechanically dispersed into a single cell suspension and cultured in vitro until cells reached confluency. These tumor cells were then subcutaneously injected into new mice. After repeating this procedure five times, a highly lung metastatic cell line, denoted as LM17, has been established. The LM17 cells grow in vitro with or without serum, whereas parental CT26 cells require serum for their growth. The LM17 cells adhere to type I collagen or fibronectin stronger than CT26 cells do. The LM17 cells invade through Matrigel-coated basement membrane in greater number than CT26 cells. By gelatin zymography, LM17 cells showed higher proteinase activity than CT26. Furthermore, subcutaneous injection of irradiated LM17 cells infected with adenovirus harboring mouse GM-CSF gene prevents the growth and lung metastasis of pre-existing subcutaneous tumor. The injection of irradiated GM-CSF-producing LM17 cells after the surgical removal of pre-existing tumor also protected the occurrence of lung metastasis. These results suggest that this highly metastatic LM17 cell line could be useful for analysis of the lung metastatic mechanism and as the mouse GM-CSF gene therapy model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11089883     DOI: 10.1023/a:1006730320248

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  13 in total

1.  Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

Authors:  E D Kwon; B A Foster; A A Hurwitz; C Madias; J P Allison; N M Greenberg; M B Burg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Selection of successive tumour lines for metastasis.

Authors:  I J Fidler
Journal:  Nat New Biol       Date:  1973-04-04

3.  Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer.

Authors:  Y Takahashi; S L Tucker; Y Kitadai; A N Koura; C D Bucana; K R Cleary; L M Ellis
Journal:  Arch Surg       Date:  1997-05

4.  Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin.

Authors:  S M Ellerbroek; D A Fishman; A S Kearns; L M Bafetti; M S Stack
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

Review 5.  Adhesive proteins and the hematogenous spread of cancer.

Authors:  G P Tuszynski; T N Wang; D Berger
Journal:  Acta Haematol       Date:  1997       Impact factor: 2.195

6.  Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo.

Authors:  R H Xing; S A Rabbani
Journal:  Endocrinology       Date:  1999-09       Impact factor: 4.736

7.  Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma.

Authors:  Z Dong; R Kumar; X Yang; I J Fidler
Journal:  Cell       Date:  1997-03-21       Impact factor: 41.582

8.  Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

Authors:  P C Brooks; S Strömblad; L C Sanders; T L von Schalscha; R T Aimes; W G Stetler-Stevenson; J P Quigley; D A Cheresh
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

9.  Surgical treatment of hepatic and pulmonary metastases from colorectal cancers.

Authors:  J F Regnard; D Grunenwald; L Spaggiari; P Girard; D Elias; M Ducreux; P Baldeyrou; P Levasseur
Journal:  Ann Thorac Surg       Date:  1998-07       Impact factor: 4.330

10.  Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.

Authors:  E Nagai; T Ogawa; T Kielian; A Ikubo; T Suzuki
Journal:  Cancer Immunol Immunother       Date:  1998-10       Impact factor: 6.968

View more
  2 in total

1.  In vitro organoid culture of primary mouse colon tumors.

Authors:  Xiang Xue; Yatrik M Shah
Journal:  J Vis Exp       Date:  2013-05-17       Impact factor: 1.355

2.  Adhesion molecule expression and function of primary endothelial cells in benign and malignant tissues correlates with proliferation.

Authors:  Wolfgang Sievert; Soile Tapio; Stephanie Breuninger; Udo Gaipl; Nicolaus Andratschke; Klaus-Rüdiger Trott; Gabriele Multhoff
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.